We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 1.14% | 445.00 | 440.00 | 450.00 | 445.00 | 440.00 | 440.00 | 11,869 | 11:13:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 47.29 | 210.93M |
TIDMTSTL
RNS Number : 1950X
Tristel PLC
19 December 2023
Tristel plc
("Tristel", the "Company", or the "Group")
AGM Statement, notice of results and planned CEO succession
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.
Paul Swinney, Chief Executive Officer, will address the meeting with the following update:
"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be GBP20.7m, an increase of 18% compared to GBP17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.
"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.
"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately GBP10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market."
Notice of Results
The Company's unaudited interim results will be announced on 26 February 2024.
CEO succession planning
In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.
The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.
Tristel plc Tel: 01638 721 500 Paul Swinney, Chief Executive Officer Liz Dixon, Chief Financial Officer Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com Charlotte Edgar Mob: 07884 664 686 Alice Woodings Mob: 07407 804 654 Cavendish Capital Markets Tel: 020 7220 0500 Limited Geoff Nash/Charlie Beeson (Corporate Finance) Sunila de Silva (ECM)
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
AGMEVLFFXLLXFBL
(END) Dow Jones Newswires
December 19, 2023 02:00 ET (07:00 GMT)
1 Year Tristel Chart |
1 Month Tristel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions